CereGate

CereGate is a Brain-Machine Interface company focused on 'mind-writing' — transmitting information into the brain via existing neuromodulation implants. Unlike hardware-focused competitors, CereGate develops a software-based interface platform that enhances treatment through conventional brain implants already on the market. The company received FDA Breakthrough Device Designation for its FOG-LIGHTS application in deep brain stimulation freezing of gait therapy for Parkinson's disease. CereGate has filed 15 patents and raised Series B funding from 468 Capital, re.Mind Capital, Heal Capital, and High-Tech Gründerfonds.